The authors write that Louwagies case report (and others) should not detract from the substantial value of GLP-1 based therapies, but they do speak yet again to the importance of individualized therapy
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
Untargeted metabolomics links these hormonal shifts to a rise in glutathione and a decline in arachidonic-acid metabolitesbiochemical signatures of reduced oxidative stress and dampened eicosanoid-driven inflammation [53]
I think the primary reason, if not the most significant reason, is creating a barrier for pharmacies to compound this medication if it goes into a shortage situation, Boesen said
Possible side effects may vary from one person to the next, as with any medication
This article describes the medicinal chemistry optimization and early preclinical evaluation of cagrilintide
